Limitin: an interferon-like cytokine without myeloerythroid suppressive properties

被引:13
作者
Oritani, K
Kincade, PW
Tomiyama, Y
机构
[1] Osaka Univ, Grad Sch Med, Dept Internal Med & Mol Sci, Suita, Osaka 5650871, Japan
[2] Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA
来源
JOURNAL OF MOLECULAR MEDICINE-JMM | 2001年 / 79卷 / 04期
基金
日本学术振兴会; 美国国家卫生研究院;
关键词
limitin; interferon; interferon-alpha/beta receptors; B lymphopoiesis; antiproliferation;
D O I
10.1007/s001090100206
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Limitin is an interferon (IFN)-like cytokine that we recently identified and cloned on the basis of its ability to arrest the growth or kill lympho-hematopoietic cells. This 182 amino acid protein has approximately 30% sequence identity with IFN-alpha, IFN-beta, and IFN-omega. Limitin binds to the IFN-alpha/beta receptors and induces IFN regulatory factor-1, thereby indicatings that limitin constitutes a new prototype of the type I IFN family. As with previously known IFNs, limitin inhibited B lymphopoiesis in vivo as well as in vitro. III addition, limitin not only modified the proliferation and function of peripheral T lymphocytes, natural killer cells, and bone marrow stromal cells but also had antiviral activity. Therefore, limitin is a multifunctional cytokine with several potential cellular targets. Because to date we have found no influence of limitin on normal myeloid and erythroid progenitors, limitin is unique among the IFNs, Type I IFN family contains TFN-alpha, IFN-beta, IFN-omega, and IFN-tau, and IFN-alpha is composed of at least 14 subtypes. All IFNs have antiproliferative, immunomodulatory, and antiviral effects and influence to each other in the body. Limitin should play a role in the complex IFN network, and its human homologue would be useful as a therapeutic agent if it lacked myelosuppressive activity.
引用
收藏
页码:168 / 174
页数:7
相关论文
共 55 条
  • [1] DIFFERENTIAL TYROSINE PHOSPHORYLATION OF THE IFNAR CHAIN OF THE TYPE-I INTERFERON RECEPTOR AND OF AN ASSOCIATED SURFACE PROTEIN IN RESPONSE TO IFN-ALPHA AND IFN-BETA
    ABRAMOVICH, C
    SHULMAN, LM
    RATOVITSKI, E
    HARROCH, S
    TOVEY, M
    EID, P
    REVEL, M
    [J]. EMBO JOURNAL, 1994, 13 (24) : 5871 - 5877
  • [2] NOMENCLATURE OF THE HUMAN INTERFERON PROTEINS
    ALLEN, G
    DIAZ, MO
    FINTER, NB
    ADOLF, GR
    DOLY, J
    LUNDGREN, E
    PESTKA, S
    ROBERTS, RM
    TESTA, D
    WIETZERBIN, J
    [J]. JOURNAL OF INTERFERON RESEARCH, 1994, 14 (04): : 223 - 226
  • [3] LPR AND GLD - SINGLE GENE MODELS OF SYSTEMIC AUTOIMMUNITY AND LYMPHOPROLIFERATIVE DISEASE
    COHEN, PL
    EISENBERG, RA
    [J]. ANNUAL REVIEW OF IMMUNOLOGY, 1991, 9 : 243 - 269
  • [4] DIRECT BINDING TO AND TYROSINE PHOSPHORYLATION OF THE ALPHA-SUBUNIT OF THE TYPE-I INTERFERON RECEPTOR BY P135(TYK2) TYROSINE KINASE
    COLAMONICI, O
    YAN, H
    DOMANSKI, P
    HANDA, R
    SMALLEY, D
    MULLERSMAN, J
    WITTE, M
    KRISHNAN, K
    KROLEWSKI, J
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 1994, 14 (12) : 8133 - 8142
  • [5] REQUIREMENT FOR MAP KINASE (ERK2) ACTIVITY IN INTERFERON-ALPHA-STIMULATED AND INTERFERON-BETA-STIMULATED GENE-EXPRESSION THROUGH STAT PROTEINS
    DAVID, M
    PETRICOIN, E
    BENJAMIN, C
    PINE, R
    WEBER, MJ
    LARNER, AC
    [J]. SCIENCE, 1995, 269 (5231) : 1721 - 1723
  • [6] Dexter T M, 1976, Methods Cell Biol, V14, P387, DOI 10.1016/S0091-679X(08)60498-7
  • [7] Domanski Paul, 1996, Cytokine and Growth Factor Reviews, V7, P143, DOI 10.1016/1359-6101(96)00017-2
  • [8] DORSHKIND K, 1988, J IMMUNOL, V141, P531
  • [9] ELIA JM, 1995, EXP HEMATOL, V23, P323
  • [10] Are all Type I human interferons equivalent?
    Foster, GR
    Finter, NB
    [J]. JOURNAL OF VIRAL HEPATITIS, 1998, 5 (03) : 143 - 152